159 related articles for article (PubMed ID: 18953066)
41. Irinogenetics: what is the right star?
Innocenti F; Vokes EE; Ratain MJ
J Clin Oncol; 2006 May; 24(15):2221-4. PubMed ID: 16636339
[No Abstract] [Full Text] [Related]
42. Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.
Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Chamnanphon M; Puangpetch A; Wongwaisayawan S; Sukasem C
Drug Metab Pharmacokinet; 2016 Feb; 31(1):90-94. PubMed ID: 26830078
[TBL] [Abstract][Full Text] [Related]
43. Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray.
Tsunedomi R; Hazama S; Okayama N; Oka M; Nagano H
Cancer Sci; 2017 Jul; 108(7):1504-1509. PubMed ID: 28474802
[TBL] [Abstract][Full Text] [Related]
44. [Importance and practice of UGT1A1 polymorphisms].
Watanabe A; Shimada T
Nihon Rinsho; 2012 Sep; 70 Suppl 7():475-9. PubMed ID: 23350445
[No Abstract] [Full Text] [Related]
45. [Importance and practice of UGT1A1 polymorphisms].
Hazama S; Oka M
Nihon Rinsho; 2011 Apr; 69 Suppl 3():351-4. PubMed ID: 22213983
[No Abstract] [Full Text] [Related]
46. [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Wang Y; Xu JM; Shen L; Xu N; Wang JW; Jiao SC; Zhang JS; Song ST; Li J; Bao HY; Yang L; Li F
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):913-6. PubMed ID: 18478930
[TBL] [Abstract][Full Text] [Related]
47. Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay.
Hasegawa Y; Sarashina T; Ando M; Kitagawa C; Mori A; Yoneyama M; Ando Y; Shimokata K
Clin Chem; 2004 Aug; 50(8):1479-80. PubMed ID: 15277366
[No Abstract] [Full Text] [Related]
48. Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer.
Fukuda M; Okumura M; Iwakiri T; Arimori K; Honda T; Kobayashi K; Senju H; Takemoto S; Ikeda T; Yamaguchi H; Nakatomi K; Matsuo N; Mukae H; Ashizawa K
Thorac Cancer; 2018 Jan; 9(1):51-58. PubMed ID: 29052349
[TBL] [Abstract][Full Text] [Related]
49. Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations.
Zhang A; Xing Q; Qin S; Du J; Wang L; Yu L; Li X; Xu L; Xu M; Feng G; He L
Pharmacogenomics J; 2007 Oct; 7(5):333-8. PubMed ID: 17060921
[TBL] [Abstract][Full Text] [Related]
50. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.
Shulman K; Cohen I; Barnett-Griness O; Kuten A; Gruber SB; Lejbkowicz F; Rennert G
Cancer; 2011 Jul; 117(14):3156-62. PubMed ID: 21287524
[TBL] [Abstract][Full Text] [Related]
51. Irinotecan in small-cell lung cancer.
Ando Y; Figg WD
N Engl J Med; 2002 May; 346(18):1414-5; author reply 1414-5. PubMed ID: 11986422
[No Abstract] [Full Text] [Related]
52. [Prediction of adverse drug reactions based on genomic information].
Sawada J; Saito Y
Nihon Rinsho; 2007 Oct; 65 Suppl 8():16-21. PubMed ID: 18074510
[No Abstract] [Full Text] [Related]
53. [Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28].
Sai K; Sawada J; Minami H
Yakugaku Zasshi; 2008 Apr; 128(4):575-84. PubMed ID: 18379174
[TBL] [Abstract][Full Text] [Related]
54. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Mehra R; Murren J; Chung G; Smith B; Psyrri A
Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
[TBL] [Abstract][Full Text] [Related]
55. Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients.
Han FF; Guo CL; Yu D; Zhu J; Gong LL; Li GR; Lv YL; Liu H; An GY; Liu LH
Cancer Chemother Pharmacol; 2014 Apr; 73(4):779-88. PubMed ID: 24519753
[TBL] [Abstract][Full Text] [Related]
56. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
Innocenti F; Ratain MJ
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):52-5. PubMed ID: 12800608
[TBL] [Abstract][Full Text] [Related]
57. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
[TBL] [Abstract][Full Text] [Related]
58. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
Campbell JM; Stephenson MD; Bateman E; Peters MD; Keefe DM; Bowen JM
Pharmacogenomics J; 2017 Jan; 17(1):21-28. PubMed ID: 27503581
[TBL] [Abstract][Full Text] [Related]
59. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
60. [Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].
Ma L; Chen Y; Yang C; Jiang H; Zhu J; Cheng Y
Zhonghua Zhong Liu Za Zhi; 2015 Jan; 37(1):29-32. PubMed ID: 25877315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
